The CSTB Knockout Raji Polyclonal Cells comprise a population of human B lymphoblast cells engineered via CRISPR/Cas9-mediated gene disruption to create a loss-of-function model for the CSTB gene. This polyclonal knockout product, generated from the Raji cell line, provides a heterogeneous pool of cells harboring targeted disruptions in CSTB, eliminating reliance on single-cell clonal selection and enabling functional studies without clonal artifacts. The polyclonal nature supports robust experimental design by mitigating clonal variability while maintaining consistent gene knockout across the population. Researchers can employ these cells to dissect CSTB-dependent mechanisms in a B-cell context, leveraging well-established assays for proteolytic regulation and cell survival pathways.
The host Raji cell line, derived from a Burkitt’s lymphoma patient, is an Epstein-Barr virus (EBV)-positive B lymphoblast model extensively used in immunology and cancer research. Raji cells exhibit characteristic features of mature B cells, including surface immunoglobulin expression and antigen-presenting capabilities, making them a relevant system for studying humoral immunity and B-cell malignancies. Their robust proliferation and well-characterized transcriptional and signaling networks facilitate detailed investigation of gene function in a lymphoma background. The EBV-immortalized status introduces additional layers of oncogenic signaling and altered apoptosis regulation, which can intersect with CSTB-related pathways, enhancing the model’s versatility for studying protease dysregulation in lymphomagenesis.
Cystatin B, encoded by CSTB, functions as an intracellular inhibitor of cysteine cathepsins, particularly cathepsins B, L, and S. This protein is transcriptionally regulated by the SP1 transcription factor and cellular stress responses, positioning it as a critical rheostat for lysosomal proteolysis. Loss of CSTB leads to unchecked cathepsin activity, resulting in lysosomal membrane permeabilization, Bid cleavage, and cytochrome c release from mitochondria, culminating in caspase-dependent apoptosis. In the context of the Raji B-cell model, the knockout disrupts the cathepsin-inhibitory balance, potentially sensitizing cells to stress-induced death or altering lysosomal function. Interactions between cystatin B and cathepsins B, L, and S, along with indirect effects on caspase activation, underscore the multifaceted role of this protease inhibitor in maintaining cellular homeostasis.
In Raji B lymphoblasts, CSTB knockout is hypothesized to impair proteolytic regulation and cell survival by unleashing cathepsin activity, which may be particularly consequential given the lymphoma-derived host’s reliance on antiapoptotic mechanisms. The EBV-positive background, with its constitutive activation of survival pathways such as NF-??B and PI3K/AKT, provides a unique environment to probe how cystatin B deficiency intersects with oncogenic signaling. The model enables dissection of lysosomal leakage-driven apoptosis and its contribution to B-cell malignancy progression or drug response. Furthermore, because Raji cells participate in antigen presentation, the knockout may influence immune-related functions, offering insights into the crosstalk between lysosomal integrity and adaptive immunity in pathological states.
The CSTB Knockout Raji Polyclonal Cells serve as a versatile tool for diverse research applications, including investigation of lysosomal storage disorders, protease dysregulation in B-cell malignancies, and disease modeling of progressive myoclonic epilepsy (EPM1). Typical experiments employ Western blotting for CSTB and cathepsin activation, cathepsin activity assays, apoptosis quantification via Annexin V staining, flow cytometry for cell cycle analysis, immunofluorescence to assess lysosomal integrity, and RNA-seq for transcriptome-wide profiling. Notably, this model is well-suited for drug sensitivity studies with proteasome inhibitors, linking cathepsin regulation to therapeutic vulnerability. For further information on experimental protocols or custom services, please contact Ascent Research.
